Sawai Pharmaceutical Completes Acquisition Of Upsher-Smith Laboratories
Sawai Pharmaceutical Co., Ltd., (Sawai) and Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced that Sawai, a leading Japanese generic pharmaceuticals manufacturer, has successfully completed its acquisition of Upsher-Smith's generics business. Sawai intends to retain operations in Minnesota and Colorado.
As previously announced, the acquisition provides Sawai with an opportunity for growth in the U.S. market where Upsher-Smith has an established, extensive portfolio of quality, high-value generic products. Rusty Field, the current President of Upsher-Smith, will take on the additional role of CEO.
"This is a momentous day for both Sawai and Upsher-Smith," said Mitsuo Sawai, President, Sawai Pharmaceutical Company. "The acquisition of Upsher-Smith adds significantly to our capabilities and supports the acceleration of our vision of becoming a globally recognized generic drug company. Upsher-Smith's manufacturing and commercial strength, strong distribution network and established relationships combined with Sawai's research and development capabilities and state-of-the-art manufacturing technology provide the opportunity to further enhance our ability to bring high-quality, high-value generic pharmaceutical products to patients both in Japan and the United States."
Rusty Field, President and CEO, Upsher-Smith added, "This acquisition brings together two closely-aligned companies with similar values. Sawai is one of the largest generic pharmaceutical companies in Japan and Upsher-Smith has an established portfolio of generic products in the United States. This deal represents an energizing growth opportunity for the generics business both in the U.S. and abroad."
Sawai's financial advisors are Torreya Partners LLC and SMBC Nikko Securities Inc., and legal counsel is Debevoise & Plimpton LLP. J.P. Morgan Securities LLC and BMO Capital Markets served as financial advisors to Upsher-Smith on this transaction and Lindquist & Vennum LLP served as the Company's legal counsel.
2026-10-24
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
China’s 15th Five-Year Plan Sets New Priorities for Pharmaceutical Innovation and Supply Chains
-
Evonik Expands Slovakian Fermas Site with €80 Million Investment to Boost Pharmaceutical CDMO Capacity
-
India's PV Community Comes Together at the 6th Edition Drug Safety Symposium 2026 – India Chapter to Shape the Future of Patient Safety
-
The project of fine chemicals with 4000 t/a Tebuconazole and Diflufenican is to be built
-
P&G launched the first major group acquisition in 2023
-
Rainbow acquires S.A. to accelerate market expansion in the EU
-
China丨Grand Holding acquired Microbe with ¥ 830 million to lay out for biopesticide industry chain
-
China丨Maxunitech acquired Shijie, became the tops in Sulfentrazone, Flumioxazin technical production capacity
-
China丨Flagchem acquired 100% equity of Suke to improve its formulation capacity
-
Pharmaconex 2022
Recommend Reading
-
Dow Chemical to Close Three European Plants, Cut 800 Jobs
-
Europe’s Chemical Industry in the Ice Age: Profits Evaporating, Plants Shutting Down, Capital Fleeing—A Systemic Collapse Is Underway
-
Nouryon Opens New Customer Experience and Innovation Center in Brazil
-
Huntsman’s Rotterdam Plant Hit by Unexpected Shutdown, Q4 EBITDA Takes a $10M Hit
-
BASF, Sinopec Forge Green Alliance to Power Nanjing Site with Certified Bio-Methane
-
Business Society, October 16, 2026: Fuel Oil 180CST Trend Analysis – Volatility
-
Business Society’s October 10, 2026 Coking Coal Market Outlook: Volatile Consolidation
-
Coke Market in October Showed Strong Performance with Price Increases Implemented
-
Ethylene Glycol Prices Stabilize and Stop Declining in Mid-to-Early July
-
Business Society October 16, 2026 MTBE Trend Analysis: Bearish Volatility